|Evan Unger, MDCo-founder, Chief Executive Officer, President|
Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on 113 issued US patents. He is a board-certified radiologist and has an appointment as a Professor of Radiology and Biomedical Engineering at the University of Arizona.
|Emmanuelle J Meuillet, PhDVP of Research and Development|
Emmanuelle J. Meuillet is an accomplished scientist, inventor and entrepreneur focusing on drug discovery and development. Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She completed post-doctoral training at the Children’s Memorial Hospital at Northwestern University in Chicago and at the University of Arizona Comprehensive Cancer Center in Tucson. She holds an appointment as an Associate Research Professor at the University of Arizona. Over the years, Dr. Meuillet has managed many NIH funded programs bringing in over $9M for research in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects. She founded two biotech companies, Phusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules. Dr. Meuillet is a consultant for the NIH, DoD, and various foundations and organizations in the US and Europe. She is the author of more than fifty peer reviewed manuscripts and reviews, she is an inventor on three patents and she belong to several editorial boards for specialized cancer journals.
|Joe Cooper, MBAChief Business Officer|
Joe’s career has included business development and operational roles within the pharmaceutical industry including serving for 14 years as Executive Vice President of Medicis Pharmaceutical Corporation where he was a member of an executive management team responsible growing a business with revenues of over $600mm In this capacity, Joseph had principal responsibility for corporate development, clinical and technical operations, business unit management, as well as frequent representation for the company with investors and equity analysts. Joe is a graduate of Northeastern Illinois University and holds a Master in Business Administration (MBA) from the Executive Program at Arizona State University. He serves as a member of the Board of Directors for Sonoran Biosciences.
|Betty R Weaver, CPAChief Financial Officer|
Ms. Weaver has over 18 years in public accounting with a regional firm in the Dallas/Fort Worth area and has principal accounting firms in Texas and Arizona. Ms. Weaver is a financial expert in providing early and expansion stage companies in Biotech and Life Sciences with planning, analysis and full CFO services. She also has over 15 years in industry with responsibility for operations, accounting, treasury, facilities, human resources and information technology. Ms. Weaver completed her BS degree in Accounting/Information Systems at University of North Texas. She holds CPA licenses in Texas and Arizona.
|Gordon Brandt, MD|
Vice President of Regulatory Affairs
Dr. Gordon Brandt has been working with NuvOx since 2012. Dr. Brandt’s career in drug, device and biologics development for US and international markets spans more than 30 years. He has led development teams resulting in both NDA and ANDA drug approvals in the US and in centralized marketing authorization for an ultrasound contrast agent in the EU. Dr. Brandt was most recently President and Executive Vice President Clinical/Regulatory at Nastech Pharmaceuticals, a publicly traded biotech company. Previously he led the clinical and regulatory development of EchoGen, a dodecafluoropentane ultrasound product which is the foundation of NuvOx technology. Dr. Brandt earned a medical degree from the University of California San Francisco and an engineering degree from Yale. Dr. Brandt is an author on 27 publications and five patents.
Board of Directors
|Dr. Evan C. UngerCo-founder, Chief Executive Officer, President|
Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials in a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx key product. Dr. Unger is inventor on 113 issued US patents. He is a board-certified radiologist and has an appointment as professor of radiology and biomedical engineering at the University of Arizona.
|Marvin J Slepian, MD|
Marvin J. Slepian, M.D. is Professor of Medicine (Cardiology), Director of Interventional Cardiology and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his Internal Medicine training at NYU-Bellevue in New York where he was a Resident and Chief Resident in Medicine. He completed his Cardiology training at Johns Hopkins where he was a Clinical and Research Fellow. He completed a second fellowship in Interventional Cardiology at Cleveland Clinic. Dr. Slepian has conducted extensive research, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of more than 25 issued and 41 filed patents. He is an expert in polymeric biomaterials and local drug delivery. Dr. Slepian has founded numerous medical device companies, including Focal (NASDAQ-traded, acquired by Genzyme), Endotex, Angiotrax and Hansen Medical, and has served as acting CEO and Board Member of several medical device startups. He earned his A.B. in Biochemical Sciences and Science in Human Affairs from Princeton University, and his M.D. from the University of Cincinnati College of Medicine. He has received additional post-doctoral training at MIT and Washington University.
|Richard Carmona MD, MPH, FACS|
Richard Carmona MD, MPH, FACS was the 17th Surgeon General of the United States and is the Distinguished Professor of Public Health at the Mel and Enid Zuckerman College of Public Health. He also holds faculty appointments as a Professor of Surgery and Pharmacy. Trained in general and vascular surgery, Dr. Carmona also completed a National Institutes of Health-sponsored fellowship in trauma, burns, and critical care. Dr. Carmona was then recruited jointly by the Tucson Medical Center and the University of Arizona to start and direct Arizona's first regional trauma care system. He went on to become the chairman of the State of Arizona Southern Regional Emergency Medical System, a professor of surgery, public health and family and community medicine at the University of Arizona, and the Pima County Sheriff's Department surgeon and deputy sheriff. He is also a Fellow of the American College of Surgeons. Dr. Carmona's interest in public health stemmed from the realization that most of his patients' illnesses and injuries were completely preventable.
|Jonathan T. Schilling|
Jonathan is retired from a 30-year career in the sale and marketing of employee benefit medical/dental plans for Blue Cross and Delta Dental. He received a BS in Information Science Management from the University of San Francisco. He is an active investor and recently invested in NuvOx and led a portion of the round totaling $1.6 Million from a group of investors. His previous investments have included Schilling Robotics (President, Tyler Schilling, Jonathan's brother), which sold in 2012 at a total valuation of several hundred million dollars. The result was an ROI of 22x for the Unit A investors. Jonathan has known Evan Unger since 1969 (high school) and now resides in San Francisco.